Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma

Hu, Jingyi; Wang, Qingqing; Liu, Yang

doi:10.3724/zdxbyxb-2021-0146

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, proteasome α-subunits have been associated with the development and progression of several types of cancers, including hepatocellular carcinoma, breast cancer, lung cancer, and multiple myeloma [19][20][21][22][23]. Certain β-subunits were as well identified as therapeutic targets in solid tumors such as hepatocellular carcinoma or kidney cancer [24,25]. However, single subunits cannot function in selective degradation of target proteins.…”

Section: Introductionmentioning

confidence: 99%

Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer

Al-Abdulla,

Venz,

Al-Ali

et al. 2023

Preprint

View full text Add to dashboard Cite

Proteasomes are involved in the maintenance of cellular protein homeostasis and the control of numerous cellular pathways. Single proteasome genes or subunits have been identified as important players in cancer development and progression without considering the proteasome as a multi-subunit protease. We here conduct a comprehensive pan-cancer analysis encompassing transcriptional, epigenetic, mutational landscapes, pathway enrichments, and survival outcomes linked to the 20S proteasome core complex. The impact of proteasome gene expression on patient survival exhibits a cancer-type dependent pattern. Escalated proteasome expression associates with elevated activation of oncogenic pathways, such as DNA repair, MYC- controlled gene networks, MTORC1 signaling, oxidative phosphorylation, as well as metabolic pathways including glycolysis and fatty acid metabolism. Vice versa, potential loss of function variants correlates with improved survival. The TCGA-derived outcomes are further supported by gene expression analysis of THP-1 cells. Our study reframes these subunits as an integrated functional ensemble, rather than separated subunits.Abstract Figure

show abstract

Section: Introductionmentioning

confidence: 99%

Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer

Al-Abdulla,

Venz,

Al-Ali

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Liver cancer is one of the most common and highly malignant solid tumors of the gastrointestinal system around the world [1] . The clinical classification of tumor includes primary and secondary.…”

Section: Introductionmentioning

confidence: 99%

Experimental Research on the Inhibitory Effect of IFN-Lambda 3 Combined with Sorafenib on the Growth of Liver Cancer Transplanted into Nude Mice

Cai

Tian

et al. 2021

PAR

View full text Add to dashboard Cite

Objective: To investigate the effect of sorafenib combined with interferon-lambda 3 on the growth of liver cancer transplanted into nude mice. Methods: Female nude mice of 4-5 weeks of age that passed quarantine were selected and fed for 1-2 weeks before experimental operation. The cell suspension of human hepatoma cell line SMMC-7721 was inoculated into the right cervical axillary fossa with a syringe. The tumor-bearing mice were randomly divided into a control group and an experimental group. The control group received normal saline whereas the experimental group was further divided into three other groups: IFN-lambda 3 treatment group, sorafenib treatment group, and IFN-lambda 3 combined with sorafenib treatment group. The situation of nude mice was analyzed. At the end of the experiment, the volume of allogeneic transplanted tumor was measured, and the morphology of tumor cells, the expression of proliferating protein Ki-67, as well as the number of apoptotic cells were observed by hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC), and TUNEL staining. Results: The tumor cell volume of the IFN-lambda 3 treatment group, sorafenib treatment group, and IFN-lambda 3 combined with sorafenib treatment group decreased, which was statistically significant compared with the control group (p < 0.05). The increment rate of proliferating protein Ki-67 in the transplanted tumor tissue of the three drug groups was significantly lower than that of the control group (p < 0.05). IFN-lambda 3 combined with sorafenib had the greatest effect on the expression level of Ki-67 protein. Compared with the control group, the expression rate was significantly lower (p < 0.05). In terms of cell apoptosis, IFN-lambda 3 and/or sorafenib, as well as the combination of the two, showed statistically significant differences compared with the control group (p < 0.05). The rate of cell apoptosis was the highest in the IFN-lambda 3 combined with sorafenib group. Conclusion: IFN-lambda 3 combined with sorafenib can inhibit the growth and proliferation of human hepatocellular carcinoma cells in nude mice and promote the apoptosis of hepatocellular carcinoma cells, which proves that IFN-lambda 3 combined with sorafenib can treat hepatocellular carcinoma in vivo.

show abstract

Prognostic Significance of ZP3 in Hepatocellular Carcinoma

Zhu

Tan

et al. 2023

CCHTS

View full text Add to dashboard Cite

Objective: The study aims to explore the prognostic significance of zona pellucida glycoprotein 3 (ZP3) in hepatocellular carcinoma (HCC) tissues. Methods: The expression of ZP3 protein in HCC tissues was detected by immunohistochemistry (IHC) to study its effects on the clinicopathological characteristics and prognosis of HCC patients. The Cancer Genome Atlas (TCGA) database was used to confirm the expression of ZP3 in HCC tissues and Gene set enrichment analysis (GSEA) was performed to obtain potential ZP3-related pathways in HCC. Results: IHC detection found that ZP3 had a high expression in HCC tissues and was associated with cirrhosis, and hepatitis B virus infection of HCC patients (P<0.05). TCGA database also showed that ZP3 was up-regulated in HCC tissues. Further survival evaluation confirmed that ZP3 expression caused an impact on the overall survival time and disease-free survival time of HCC patients (P<0.05), implying a potential role in HCC prognosis. GSEA analysis indicated that the 187 differential gene sets were mainly involved in 10 signaling pathways, including 5 up-regulated and 5 down-regulated pathways. Conclusion: High expression of ZP3 in HCC tissues shows an important role in HCC development and prognosis.

show abstract

Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma

Cited by 3 publications

References 28 publications

Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer

Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer

Experimental Research on the Inhibitory Effect of IFN-Lambda 3 Combined with Sorafenib on the Growth of Liver Cancer Transplanted into Nude Mice

Prognostic Significance of ZP3 in Hepatocellular Carcinoma

Contact Info

Product

Resources

About